Drug Trial Radar · NCT07840287
A Long-Term Extension (LTE) Study Of Enpatoran In Cutaneous Manifestations Of Lupus With Or Without Systemic Disease [Elowen-LTE]
Last checked: Nov 19, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
404
Planned (sponsor's estimate)
Start
Oct 22, 2026
Primary completion
Sep 1, 2031
Study completion Sep 1, 2031
Sponsor
- Lead sponsor
- EMD Serono Research & Development Institute, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- Merck KGaA, Darmstadt, Germany
- First posted
- Sep 25, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 76 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the long-term safety and efficacy of orally administered enpatoran in participants with cutaneous manifestations of lupus erythematosus who have completed the Elowen-1 (MS504908\_0001) (NCT07332481) and Elowen-2 (MS504908\_0008) (NCT07355218) study treatment and to provide participants an opportunity to receive active treatment with enpatoran for up to 108 weeks in this open-label study. Study details include: Study Duration: 120 weeks. Treatment Duration: 108 weeks. Visit Frequency: Every 4 weeks (from Week 4 to Week 24) and every 12 weeks (from Week 36 to Week 120). Study Intervention: Enpatoran. Intervention Form: Film-coated tablet.
Conditions
- Systemic Lupus Erythematosus (SLE)
- Cutaneous Lupus Erythematosus (CLE)
Interventions
EnpatoranDrug
Participants will receive a dose of Enpatoran orally for 108 weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Treatment Emergent adverse events (TEAEs), Serious Adverse Events (SAEs), and Adverse Events of Special Interest (AESI)Time frame: From current LTE study Day 1 to Week 120
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Revival Research Institute, LLC
Troy, Michigan · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.